In a surprising pivot, MEI Pharma has rebranded as Lite Strategy, Inc. (NASDAQ: LITS) and transformed its focus from biotech to digital asset treasury management. The company is now the first US-listed firm to adopt Litecoin (LTC) as its primary reserve asset (MEI Pharma Investor Relations).
Why did MEI Pharma rebrand as Lite Strategy?
The rebrand reflects a complete shift in business model. Management believes blockchain and digital asset reserves offer greater long-term potential than its drug pipeline. By embracing Litecoin, the company positions itself as a pioneer in digital asset treasury strategy (Nasdaq).
How is Lite Strategy building its Litecoin treasury?
In August 2025. Lite Strategy raised $100 million in a private placement to launch its Litecoin treasury plan. The firm acquired about 929.548 LTC at an average of $107.58 per token, bringing its initial holdings to around $110 million in value (MEI Pharma release).
Who is guiding the new strategy?
Lite Strategy partnered with GSR, a global digital asset markets firm, to structure and manage its treasury. It also brought Litecoin's creator, Charlie Lee, onto its board of directors, giving the project both credibility and insider expertise (MEI Pharma release).
What does this mean for Litecoin adoption?
Lite Strategy's move boosts institutional credibility for Litecoin, which has long been overshadowed by Bitcoin and Ethereum. Investors saw the rebrand as bullish for LTC, with trading activity and whale interest increasing after the announcement (Yahoo Finance).
Conclusion
Lite Strategy has made one of the boldest corporate pivots in recent memory—abandoning biotech for blockchain. By anchoring itself to Litecoin, the company not only reshapes its own future but also pushes LTC further into the spotlight as a corporate reserve asset.
